Loading
Healthy Participants / Elecoglipron Test formulation 1 Dose B / Elecoglipron Test formulation 1 Dose A · Phase 1 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registry record for a relative bioavailability study of oral elecoglipron formulations sponsored by AstraZeneca. The study is actively recruiting and has not yet reported results. No efficacy, safety, or pharmacokinetic outcome data are available from this registry entry.
Phase 1, Interventional, Randomized, Crossover, Open label, Treatment purpose. Healthy Participants; age from 18 Years; to 55 Years; accepts healthy volunteers. Intervention: Cohort 1-Treatment Sequence A; Cohort 1 - Treatment Sequence B; Cohort 2 - Treatment Sequence C; Cohort 2 - Treatment Sequence D; Cohort 3 - Treatment Sequence E; Cohort 3 - Treatment Sequence F; Cohort 4 - Treatment Sequence G; Cohort 4 -…. Compared with: Elecoglipron reference formulation at Dose A and Dose B. n = 152. 2 sites: United States.
This is a Phase 1 clinical trial registry record for a relative bioavailability study of oral elecoglipron formulations sponsored by AstraZeneca. The study is actively recruiting and has not yet reported results. No efficacy, safety, or pharmacokinetic outcome data are available from this registry entry.
Healthy volunteer population limits inference to clinical efficacy or tolerability in patients. No numerical results for any pharmacokinetic parameter or bioavailability ratio are provided in this source.
This early-phase study addresses formulation development and will not directly inform clinical practice until Phase 2/3 efficacy and safety data are available for elecoglipron in the target disease population.
Phase 1 bioavailability study in healthy volunteers with no results posted; registry record only documents planned pharmacokinetic endpoints without outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This early-phase study addresses formulation development and will not directly inform clinical practice until Phase 2/3 efficacy and safety data are available for elecoglipron in the target disease population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07723833). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 152 participants (ESTIMATED). Conditions: Healthy Participants. Interventions: DRUG: Elecoglipron Reference Formulation Dose A; DRUG: Elecoglipron Test formulation 1 Dose A; DRUG: Elecoglipron Reference Formulation Dose B; DRUG: Elecoglipron Test formulation 1 Dose B; DRUG: Elecoglipron Test formulation 2 Dose A; DRUG: Elecoglipron Test formulation 2 Dose B. Primary outcome measures: Maximum observed drug concentration (Cmax) , At pre-defined intervals from Day 1 to Day 15; Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) , At pre-defined intervals from Day 1 to Day 15; Area under concentration-time curve from time 0 to infinity (AUCinf) , At pre-defined intervals from Day 1 to Day 15; Time to reach maximum observed concentration (tmax) , At pre-defined intervals from Day 1 to Day 15; Terminal elimination rate constant (λz) , At pre-defined intervals from Day 1 to Day 15; Terminal elimination half-life (t1/2λz) , At pre-defined intervals from Day 1 to Day 15; Apparent total body clearance (CL/F) , At pre-defined intervals from Day 1 to Day 15; Apparent volume of distribution based on the terminal phase (Vz/F) , At pre-defined intervals from Day 1 to Day 15; Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf) , At pre-defined intervals from Day 1 to Day 15; Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast) , At pre-defined intervals from Day 1 to Day 15; Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax) , At pre-defined intervals from Day 1 to Day 15. Brief summary: The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.